Authors: Lubbert, M Wijermans, P Kunzmann, R Verhoef, G Bosly, A Ravoet, C Andre, M Ferrant, A

Citation: M. Lubbert et al., Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2 '-deoxycytidine, BR J HAEM, 114(2), 2001, pp. 349-357

Authors: Tassin, F Dewe, W Schaaf, N Herens, C Ravoet, C Albert, A Beguin, Y Paulus, JM

Citation: F. Tassin et al., A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes, LEUK LYMPH, 36(5-6), 2000, pp. 485-496

Authors: Wijermans, P Lubbert, M Verhoef, G Bosly, A Ravoet, C Andre, M Ferrant, A

Citation: P. Wijermans et al., Low-dose 5-aza-2 '-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients, J CL ONCOL, 18(5), 2000, pp. 956-962

Authors: Mounier, N Haioun, C Cole, BF Gisselbrecht, C Sebban, C Morel, P Marit, G Bouabdallah, R Ravoet, C Salles, G Reyes, F Lepage, E

Citation: N. Mounier et al., Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission, BLOOD, 95(12), 2000, pp. 3687-3692

Authors: van Baren, N Brasseur, F Godelaine, D Hames, G Ferrant, A Lehmann, F Andre, M Ravoet, C Doyen, C Spagnoli, GC Bakkus, M Thielemans, K Boon, T

Citation: N. Van Baren et al., Genes encoding tumor-specific antigens are expressed in human myeloma cells, BLOOD, 94(4), 1999, pp. 1156-1164

Authors: Schapira, M Henrion, J Ravoet, C Maisin, JM Ghilain, JM De Maeght, S Heller, F

Citation: M. Schapira et al., Thromboembolism in inflammatory bowel disease, ACT GASTR B, 62(2), 1999, pp. 182-186